Goldman Sachs’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-508,062
| Closed | -$19.5M | – | 6036 |
|
|
2023
Q2 | $19.5M | Buy |
508,062
+158,756
| +45% | +$4.08M | ﹤0.01% | 1873 |
|
|
2023
Q1 | $8.09M | Buy |
349,306
+137,130
| +65% | +$3.27M | ﹤0.01% | 2626 |
|
|
2022
Q4 | $5.56M | Sell |
212,176
-190,414
| -47% | -$4.22M | ﹤0.01% | 3067 |
|
|
2022
Q3 | $7.92M | Buy |
402,590
+168,861
| +72% | +$3.39M | ﹤0.01% | 2723 |
|
|
2022
Q2 | $4.09M | Sell |
233,729
-1,009
| -0.4% | -$15.8K | ﹤0.01% | 3342 |
|
|
2022
Q1 | $3.84M | Buy |
234,738
+16,512
| +8% | +$224K | ﹤0.01% | 3607 |
|
|
2021
Q4 | $3.56M | Buy |
218,226
+23,289
| +12% | +$332K | ﹤0.01% | 3735 |
|
|
2021
Q3 | $2.49M | Buy |
194,937
+41,407
| +27% | +$545K | ﹤0.01% | 3986 |
|
|
2021
Q2 | $2.17M | Buy |
153,530
+134,625
| +712% | +$2.15M | ﹤0.01% | 4134 |
|
|
2021
Q1 | $294K | Sell |
18,905
-1,893
| -9% | -$30.9K | ﹤0.01% | 5441 |
|
|
2020
Q4 | $330K | Buy |
20,798
+7,860
| +61% | +$119K | ﹤0.01% | 4845 |
|
|
2020
Q3 | $157K | Sell |
12,938
-34,125
| -73% | -$457K | ﹤0.01% | 4991 |
|
|
2020
Q2 | $544K | Buy |
47,063
+32,354
| +220% | +$446K | ﹤0.01% | 4339 |
|
|
2020
Q1 | $201K | Sell |
14,709
-140,275
| -91% | -$1.66M | ﹤0.01% | 4704 |
|
|
2019
Q4 | $914K | Buy |
154,984
+125,554
| +427% | +$682K | ﹤0.01% | 4183 |
|
|
2019
Q3 | $156K | Sell |
29,430
-42,513
| -59% | -$282K | ﹤0.01% | 4887 |
|
|
2019
Q2 | $554K | Buy |
71,943
+21,133
| +42% | +$322K | ﹤0.01% | 4347 |
|
|
2019
Q1 | $1.01M | Buy |
50,810
+1,520
| +3% | +$26.5K | ﹤0.01% | 4050 |
|
|
2018
Q4 | $651K | Buy |
49,290
+18,532
| +60% | +$370K | ﹤0.01% | 4222 |
|
|
2018
Q3 | $1.13M | Sell |
30,758
-6,471
| -17% | -$208K | ﹤0.01% | 3972 |
|
|
2018
Q2 | $1.3M | Sell |
37,229
-40,512
| -52% | -$1.55M | ﹤0.01% | 3899 |
|
|
2018
Q1 | $3.62M | Buy |
77,741
+18,940
| +32% | +$693K | ﹤0.01% | 3152 |
|
|
2017
Q4 | $2.21M | Buy |
58,801
+20,195
| +52% | +$882K | ﹤0.01% | 3710 |
|
|
2017
Q3 | $2.06M | Sell |
38,606
-5,609
| -13% | -$333K | ﹤0.01% | 3960 |
|
|
2017
Q2 | $2.52M | Sell |
44,215
-3,129
| -7% | -$157K | ﹤0.01% | 3648 |
|
|
2017
Q1 | $2.54M | Buy |
47,344
+36,347
| +331% | +$2.05M | ﹤0.01% | 3508 |
|
|
2016
Q4 | $627K | Buy |
10,997
+5,756
| +110% | +$348K | ﹤0.01% | 4860 |
|
|
2016
Q3 | $326K | Buy |
5,241
+565
| +12% | +$39.9K | ﹤0.01% | 5413 |
|
|
2016
Q2 | $264K | Sell |
4,676
-4,962
| -51% | -$302K | ﹤0.01% | 5455 |
|
|
2016
Q1 | $617K | Buy |
9,638
+2,338
| +32% | +$189K | ﹤0.01% | 4538 |
|
|
2015
Q4 | $1.03M | Buy |
+7,300
| New | +$991K | ﹤0.01% | 4268 |
|
Goldman Sachs's KDNY Position: Q3 2023 in Review
Goldman Sachs sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 508,062 shares — an estimated $19.5M sold.
Goldman Sachs first reported a position in KDNY in Q4 2015 and held it in 31 quarters. The position peaked at $19.5M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Goldman Sachs reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Goldman Sachs sold 508,062 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $19.5M.
- Goldman Sachs first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 31 quarters.
- Goldman Sachs's Chinook Therapeutics, Inc. Common Stock position peaked at $19.5M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.